BOARD OF DIRECTORS

The Board of Directors of Biosys UK Limited combines expertise across industry, academia, drug development and the investment community, unified by a mission to improve the lives of patients

Stefan Ullrich, MD, PhD: CEO

Stefan is the CEO of Biosys UK Limited following several years as a physician Stefan spent almost 25 years in positions, with growing responsibilities, in the pharmaceutical industry (big pharma corporations and biotech-start-ups) including Medical, Clinical Research, Pharmacovigilance, medical preparation and realization of various product launches. Most recently he held the position of Chief Medical Officer with international responsibilities.  Stefan has held positions at American Cyanamid (Lederle Pharma), Wyeth, Schering-Plough (Essex Pharma), Wilex, Elan/ Zeneus/ Cephalon/ Teva, iQone. Stefan holds an MD and PhD in Munich

Gunnar Weikert, MD, PhD, MBA: Non-executive Director

Gunnar is the Chairman and Founder of Inventages, one of the world’s largest specialised life science investors. He was previously a Senior VP at Bayer AG, and has more than 20 years experience in the life sciences industry.

Kai Joachimsen, MD, MBA: Non-executive Director

Kai is a senior executive with a strong background in the pharmaceutical Industry and healthcare industries.  Kai is a certified doctor., with MBA studies in Germany and the USA.  After his time in surgery, he held positions in leading pharmaceutical companies such as GSK, Boehringer Ingelheim, Merck Sharp and Dohme and Chiesi GmbH Germany.  Most recently he held the position of Group Chief Executive Officer at OmniaMed Holding.  Kai has an MD (University of Münster) and MBA (Kellogg School of Management).

Axel Wiest, MD, PhD, MPH: Non-executive Director

Axel is a senior executive with several years of experience in the biopharmaceutical and healthcare industries. He is currently SVP/COO R&D and Head of Global Strategy and Business Operations R&D at Merck Biopharma. Previously he held leadership roles at Boehringer Ingelheim Biopharmaceuticals and Fresenius.